Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01316692 | Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma | terminated | Phase 2 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 30, 2016 | clinicaltrials |
| NCT00991991 | Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma | terminated | — | 5 | Case Comprehensive Cancer CenterOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00897312 | Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease | terminated | — | 7 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 25, 2016 | clinicaltrials |
| NCT00716495 | Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | AGIRx Ltd.INDUSTRY | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00613509 | Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma | terminated | Phase 2 | 23 | Sanofi Pasteur, a Sanofi CompanyINDUSTRY | 2 | Apr 14, 2016 | clinicaltrials |
| NCT01700114 | Post-Approval Study of MelaFind | terminated | — | 487 | MELA Sciences, Inc.INDUSTRY | 1 | Mar 11, 2016 | clinicaltrials |
| NCT01730157 | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases | terminated | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01200342 | Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 11, 2016 | clinicaltrials |
| NCT00673361 | Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma | terminated | Phase 2 | 9 | Duke UniversityOTHER | 0 | Jan 13, 2016 | clinicaltrials |
| NCT00568451 | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT00003715 | Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | terminated | Phase 2 | 425 | AVAX TechnologiesINDUSTRY | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 30, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01474551 | Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00704938 | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer | terminated | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00706992 | Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01160445 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01273181 | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT01783431 | Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells | terminated | Phase 1 | 1 | Medical University of South CarolinaOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT01045915 | Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma(AMEP) | terminated | Phase 1 | 5 | Valerio TherapeuticsINDUSTRY | 3 | Sep 11, 2015 | clinicaltrials |
| NCT00996827 | Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma | terminated | — | 100 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 18, 2015 | clinicaltrials |
| NCT00776945 | Feasibility and Functionality of fPAM Imaging in Melanoma(fPAM) | terminated | — | 2 | Washington University School of MedicineOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01085396 | Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on Skin | terminated | — | 16 | University of PittsburghOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT01216436 | Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma | terminated | Phase 1 | 2 | Duke UniversityOTHER | 1 | May 25, 2015 | clinicaltrials |
| NCT02442466 | Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma | terminated | Early Phase 1 | 5 | MelCure SAINDUSTRY | 0 | May 20, 2015 | clinicaltrials |
| NCT00482105 | Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells(DermTech) | terminated | N/A | 7 | University of California, DavisOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT00072189 | A Phase II Study of UCN-01 in Metastatic Melanoma | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT01400451 | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | terminated | Phase 1 | 18 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 1, 2015 | clinicaltrials |
| NCT01835184 | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01123304 | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 17, 2014 | clinicaltrials |
| NCT01212276 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT01519427 | Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2014 | clinicaltrials |
| NCT00087373 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jun 9, 2014 | clinicaltrials |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Prisma Health-UpstateOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT01068470 | Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy(LAK) | terminated | — | 11 | Loma Linda UniversityOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00005841 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 1 | 15 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00006113 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 2 | 25 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184067 | Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma | terminated | Phase 2 | 23 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT01166126 | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00522834 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | terminated | Phase 3 | 630 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Mar 4, 2014 | clinicaltrials |
| NCT01055522 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma | terminated | Phase 2 | 102 | Philogen S.p.A.INDUSTRY | 4 | Feb 25, 2014 | clinicaltrials |
| NCT00402662 | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | terminated | Phase 2 | 3 | Yale UniversityOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00358319 | Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma | terminated | Phase 1 / Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01944709 | Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma | terminated | Phase 1 / Phase 2 | 2 | Prof. Dr. Silke GillessenOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00147550 | MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. | terminated | Phase 1 / Phase 2 | 79 | PfizerINDUSTRY | 1 | Sep 13, 2013 | clinicaltrials |
Data updated 22 days agoSource updated May 30, 2016source: clinicaltrials